Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut

ByThe Short Paper

This study explored a treatment combination (obinutuzumab, ibrutinib, and venetoclax) for a specific type of leukemia (chronic lymphocytic leukemia with del(17p) and/or TP53 mutation) in previously untreated patients. The treatment involved several cycles and aimed to achieve complete remission.

The results showed that 58.5% of patients achieved complete remission, and after around 3 years, the progression-free survival rate was 79.9%, with an overall survival rate of 92.6%. Some patients experienced side effects like neutropenia, infections, and cardiovascular issues, but these generally decreased over time.

In summary, this treatment regimen appears promising for high-risk chronic lymphocytic leukemia patients with manageable side effects.

Similar Posts

CAR-T Cell Therapy will it work? Biotech Stocks Part 1

ByThe Short Paper

Disclaimer: I do not have a background in finance. I do have a background in medicine. I’m writing about CAR-T cell therapy because it’s been something I’ve been interested in for a while. I am not sure what impact it will have on biotech stocks or company valuations, but I believe it could be significant….

Fasting-mimicking diet and hormone therapy induce breast cancer regression

ByThe Short Paper

Article In a mouse model, this study demonstrated that receptor positive breast cancer are affected by a fasting diet. This is effected by decreasing certain hormones (insulin, leptin, etc.). They found combined with a specific treatment (oestrogen therapy) a fasting like diet further decreased these hormones that are negatively associated in these cancers. TL;DR A…

Simple Summary – Immediate Transfusion in African Children with Uncomplicated Severe Anemia

ByThe Short Paper

Link to the paper: https://www.nejm.org/doi/full/10.1056/NEJMoa1900105 The World Health Organization, WHO, has specific guidelines for transfusion in African countries due to the scarcity of blood products. Patients with extreme anemia do not necessarily receive transfusion unless fitting specific guidelines. The WHO guideline cutoff values are substantially less than values used in other areas of the world. This…

Summary – A Prospective, Randomized Clinical Trial of Efficacy in Coagulopathic Cardiac Surgery Patients

ByThe Short Paper

Link to the paper: https://www.ncbi.nlm.nih.gov/pubmed/22914710 Introduction It’s been found that the usage of allogenic blood products are independently associated with increased mortality and adverse events. In literature, it states that an accurate diagnosis of underlying hemostatic pathology is important and so having an algorithm driven hemostatic therapy is important and found to be better than clinical…

Child wasting and concurrent stunting in low- and middle-income countries

ByThe Short Paper

The goal is to end child malnutrition by 2030, which includes tackling “child wasting,” where kids are too thin for their height. Traditional methods for measuring this problem only give a snapshot, missing when it starts and ends. This study looked at data from 21 groups of children and found that child wasting is a…

How Bureaucrats Impact Prices and Quality in Russia’s Procurement Process

ByThe Short Paper

Individuals and Organizations as Sources of State Effectiveness Bureaucrats play a crucial role in a state’s productivity, affecting the prices paid for goods and services. In Russia, individual bureaucrats and organizations managing procurement have a significant impact, with 39% of price variation attributed to them. Effective bureaucrats tend to achieve lower prices while maintaining quality….